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Abstract: A series of 6,7-disubstituted-3-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}quinazoline-
2,4(1H,3H)-dione derivatives (7-34) were synthesized and their structures were elucidated on the basis 




C-NMR and MS) data. These synthesized compounds 
were evaluated for their in vitro cytotoxicities against a panel of three human cancer cell lines. Ac-
cording to the cytotoxicity screening results, 3-{2-[4-(4-chlorobenzyl)piperazin-1-yl]-2-oxoethyl} 
quinazoline-2,4(1H,3H)-dione (7) presented the highest activity against HUH-7, MCF-7 and HCT-116 
cell line with the IC50 values of 2.5, 6.8 and 4.9 µM, respectively. 
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1. INTRODUCTION 
Cancer is one of the potentially fatal diseases, which is 
characterized by uncontrolled division of a group of cells 
leading to metastasis and invasion to adjacent tissues. Al-
though many chemotherapeutic agents are in clinical use, 
synthesizing new anticancer agents with less side effect and 
increased selectivity is still ongoing area of interest in me-
dicinal chemistry. Since the discovery of gefitinib (Fig. 1), 
quinazolines has attracted considerable attention in the de-
sign of new chemotherapeutic agents. Some 4-
anilinoquinazolines (erlotinib, vandetanib, lapatinib, afatinib 
and trimetrexate) and 4-quinazolinone derivative (raltitrexed) 
(Fig. 1) have been introduced into clinical use for the treat-
ment of several types of cancer. It was reported that, quina-
zolines which act as adenosine triphosphate (ATP)-mimic 
compounds show their tyrosine kinase enzyme inhibition 
activities by occupying the ATP-binding pocket with high 
affinity [1-4]. Quinazolines may also exhibit their anticancer 
activity by both p53 modulation and thyroid-stimulating 
hormone receptor (TSHR) agonistic activity [5, 6]. 
Various literatures report numerous 2,4(1H,3H)-
quinazolinedione analogues showing a wide variety of bio-
logical activities such as anticancer [7-20], antimicrobial 
[21-37], antihypertensive [38-40], anticonvulsant [41-49], 
anti-inflammatory [50], 5-hydroxytryptamine 3 (5-HT3) re-
ceptor antagonist [51], phosphodiesterase (PDE) 4 inhibition 
[52,53], calcium-independent phosphodiesterase enzyme 
inhibition (CaIPDE) [54], cyclin-dependent kinase 5 (CDK5) 
inhibition [55], 5-HT3A receptor antagonist [56], antioxidant 
[57] and antiplatelet [58].
 
Some 3,6,7-trisubstituted-2,4-  
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quinazolinedione derivatives were recently submitted to NCI 
antitumor screening program. Four of them (1, Fig. 2) sig-
nificantly inhibited growth of 60 human tumor cell in vitro 
with IC50 values ranging from 0.4 to 0.8 µM [7]. 3-
Substituted-2,4-quinazolinedione derivative (2, Fig. 2) was 
patented for its cytotoxicity with IC50 value below than 10 
nM againts human ovarian cancer (SKOV3) cell line [8].  
On the other hand, a comprehensive literature study 
shows that piperazines are a significant class of heterocyclic 
compound with their various biological properties (Fig. 3), 
especially potential antitumour activity. Tahmatzopoulos et 
al. reported that the doxazosin and terazosin, α1-
adrenoceptor antagonists, could generate apoptosis in benign 
and malignant prostate cells, also decrease tumor vascularity 
in prostate tumors and suppress prostate tumorigenic growth 
in vivo [59]. 
In the light of these observations, with the aim of discov-
ering new anticancer agents, a series of 6,7-disubstituted- 
3-{2-[4-(substituted)piperazin-1-yl]-2-oxoethyl}quinazoline-
2,4(1H,3H)-dione derivatives were synthesized (Fig. 4) and 
their in vitro cytotoxicities were evaluated against three hu-
man cancer cell lines, hepatoma (HUH-7), breast cancer 
(MCF-7) and colorectal cancer (HCT-116) by using Sulfor-
hodamine B test. 
2. RESULTS AND DISCUSSION 
2.1. Chemistry 
The synthetic routes for 3-substituted-2,4(1H,3H)-
quinazolinedione derivatives are summarized in Scheme (1). 
Synthesis of 2,4(1H,3H)-quinazolinedione ring deriva-
tives started with the nucleophilic addition reaction of the 2-
aminobenzoic acid derivatives to ethyl isocyanatoacetate 
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leading to the formation of corresponding 2-(3-ethoxy-
carbonylmethylureido)benzoic acid derivatives. Reactions 
were carried out by stirring the reactants in saturated potas-
sium bicarbonate solution at room temperature to give mod-
erate yields of urea derivatives (30-54%, 1-3). Spectral data 
and melting point of the compound 1 were in accordance 
with the values of published before [60]. 
2-(3-Ethoxycarbonylmethylureido)benzoic acid deriva-
tives (1-3) were refluxed in concentrated hydrochloric acid 
for 2 hours to give 2,4-dioxo-1,4-dihydroquinazolin-3(2H)-
yl)acetic acid derivatives (4-6) in moderate to good yields of 
36-73%. The compounds were easily seperated from the 
reaction media without using any purification techniques. 
Ring closure reaction was carried out by heating compound 
1-3 in acidic media, as well as the ester functional group 
were hydrolysed to carboxylic acid to yield compound 4-6.  
Final compounds (7-34) were prepared by the amidation 





































































































a: R1=2-chlorophenylethyl, R2=methoxy, R3=2-chloro
b: R1=3-chlorophenylethyl, R2=4-methylpiperazine-1-yl, R3=3-chloro
c: R1=2-chlorophenylethyl, R2=4-methoxypiperazine-1-yl, R3=3-chloro
d: R1=phenyl, R2=methoxy, R3=2-chloro  
Fig. (2). Some cytotoxic 2,4(1H,3H)-quinazolinedione derivatives. 
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acid derivatives (4-6) with various 1-substitutedpiperazines. 
Reactants were stirred with the coupling reagent N,N'-
dicyclohexylcarbodiimide (DCC) in nitrogen atmosphere at 
cold (0-5 °C) to room temperature for 10-16 hours. Reaction 
solvent was evaporated to dryness. The residue was dis-
solved in hot acetonitrile then cooled in refrigerator to get 
the N,N′-dicyclohexylurea (DCU) precipitated. White crys-
talline DCU was removed by filtration. The liquid part was 
evaporated and crystallized from appropriate solvents. Com-













Fig. (4). General formula of target compounds.  
2.2. Tumor Cell Growth Inhibition Studies  
All synthesized compounds were examined for their cy-
totoxic activity against hepatoma (HUH-7), breast cancer 
(MCF-7) and colorectal cancer (HCT-116) cell line with  
 
 
using Sulforhodamine B assay. According to the cytotoxicity 
data, some compounds exhibited cytotoxic activitiy between 
the values of 2.5-19.0 µM (Table 1).  
3-{2-[4-(4-Chlorobenzyl)piperazin-1-yl]-2-oxoethyl}qui-
nazoline-2,4(1H,3H)-dione (compound 7) presented the 
highest activity against HUH-7, MCF-7 and HCT-116 with 
the IC50 values of 2.5, 6.8 and 4.9 µM, respectively. 6-
Chloro derivative (compound 15) of this compound exhib-
ited lower activity against these three cell lines than com-
pound 7 with IC50 values of 7.0 µM, 13.1 µM and 9.4 µM, 
whereas 6,7-dimethoxy derivative (compound 25) showed 
moderate cytotoxicity against HCT116 with IC50 value of 
16.9 µM and no cytotoxicity against HUH-7 and MCF-7 cell 
lines (Table 2).  
Compound 8 presented cytotoxicity over HUH-7, MCF-7 
and HCT-116 cell lines with IC50 values of 11.5, 12.2 and 
35.3 µM, respectively. But 6-chloro (compound 17) and 6,7-
dimethoxy derivative (compound 27) of this compound did 
not show any activity against these three cell lines.  
Compound 16 bearing 6-chloro atom on the 2,4-
quinazolinedione ring exhibited moderate activity against 





































































Fig. (3). Some clinically used piperazine derivatives. 










































i. saturated KHCO3 solution, rt, 1h.
ii. concd. HCl, reflux, 2h.
iii. 1-substitutedpiperazine, DCC, DCM, 0 oC (0.5h)- rt (10-16h)
 
Scheme (1). General synthetic pathway of the target compounds 7-34. 
Table 1. IC50 values for tested compounds 7-34 against hepatoma cell line (HUH-7), breast cancer cell line (MCF-7) and colorectal 
cancer cell line (HCT-116) using Sulforhodamine B assay. (
a
Camptothecin was positive control, 
b
5-fluorouracil was refer-













IC50 Values (µM) 
 R1 R2 A 
HUH-7 MCF-7 HCT-116 
7 -H -H 4-chlorobenzyl 2.5 6.8 4.9 
8 -H -H 1,3-benzodioxol-5-ylmethyl 11.5 12.2 35.3 
9 -H -H 2-furoyl - - - 
10 -H -H cyclohexyl - - - 
11 -H -H 2-cyanophenyl - - - 
12 -H -H diphenylmethyl - 15.2 - 
13 -H -H benzoyl - - - 
14 -H -H 4-pyridyl - - - 
15 -Cl -H 4-chlorobenzyl 7.0 13.1 9.4 
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Table 1. contd… 
IC50 Values (µM) 
 R1 R2 A 
HUH-7 MCF-7 HCT-116 
17 -Cl -H 1,3-benzodioxol-5-ylmethyl - - - 
18 -Cl -H 2-furoyl - - - 
19 -Cl -H cyclohexyl - - - 
20 -Cl -H 2-cyanophenyl - - - 
21 -Cl -H diphenylmethyl 9.2 13.0 9.0 
22 -Cl -H 4-methoxyphenyl - - - 
23 -Cl -H benzoyl - - - 
24 -Cl -H 4-pyridyl - - - 
25 -OCH3 -OCH3 4-chlorobenzyl - - 16.9 
26 -OCH3 -OCH3 3-trifluoromethylphenyl - - 6.0 
27 -OCH3 -OCH3 1,3-benzodioxol-5-ylmethyl - - - 
28 -OCH3 -OCH3 2-furoyl - - - 
29 -OCH3 -OCH3 cyclohexyl - - 11.4 
30 -OCH3 -OCH3 2-cyanophenyl - - 19.0 
31 -OCH3 -OCH3 diphenylmethyl - - 9.9 
32 -OCH3 -OCH3 4-methoxyphenyl - - - 
33 -OCH3 -OCH3 benzoyl - - - 
34 -OCH3 -OCH3 4-pyridyl - - - 
Camptothecina 0.00131 2.4×10-6 9.2×10-7 
5-Flourouracilb 30.70 3.5 18.78 
 













Compound R1 R2 HUH-7 MCF-7 HCT-116 
7 -H -H 2.5 6.8 4.9 
15 -Cl -H 7.0 13.1 9.4 
25 -OCH3 -OCH3 - - 16.9 
 
18.6 µM, whereas no activity against these cell lines was 
observed for the 6,7-dimethoxy derivative (compound 26). 
Compound 26 only presented cytotoxic activity against 
HCT-116 with IC50 value of 6.0 µM. 
 
Diphenylmethyl derivative of 6-chloro-2,4-quinazoline-
dione (compound 21) showed cytotoxicity against HUH-7, 
MCF-7 and HCT-116 cell lines with IC50 values of 9.2 µM, 
13 µM and 9 µM, respectively. Its non-substituted derivative  
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(compound 12) only exhibited cytotoxicity over MCF-7 cell 
line with IC50 value of 15.2 µM, whereas 6,7-dimethoxy de-
rivative (compound 31) only showed cytotoxicity over HCT-
116 cell line with IC50 value of 9.9 µM.  
Only the compounds 25, 26 and 29-31 presented IC50 
values ranging from 6 to19 µM against HCT-116 cell line. 
But generally, 6,7-dimethoxy derivatives (compound 25-34) 
was non-cytotoxic over HUH-7, MCF-7 cell lines (Table 3). 
3. MATERIALS AND METHODS  
3.1. Chemical Methods  
Infrared Spectra were recorded on a Perkin-Elmer Spec-
trum One series FT-IR apparatus (Version 5.0.1), using po-







C-NMR spectra were recorded 
with a Varian Mercury-400 FT-NMR spectrometer (Varian 
Inc., Palo Alto, CA, USA), using tetramethylsilane (TMS) as 
the internal reference, with deuterated-dimethyl sulfoxide 
(DMSO-d6) as solvent, the chemical shifts were reported in 
parts per million (ppm). Elemental analyses were performed 
on LECO 932 CHNS (Leco-932, St. Joseph, MI, USA) in-
strument. Liquid chromatography-mass spectrometry (LC-
MS) spectra were recorded with a Waters 2695 Alliance Mi-
cromass ZQ instrument using electrospray ionization (ESI) 
technique. 
General procedure for compounds 1-3. A solution of 
2-aminobenzoic acid derivative (0.026 mol) in 35 ml of satu-
rated potassium bicarbonate (KHCO3) solution was stirred 
with 3.3 ml of ethyl isocyanatoacetate for an hour at room 
temperature. The solution was acidified with concentrated 
hydrochloric acid and filtered. The precipitate was crystal-
lized from ethanol. 
2-[3-(2-Ethoxy-2-oxoethyl)ureido]benzoic acid (1). 2-
Aminobenzoic acid (7.056 g, 0.026 mol) and ethyl isocyana-
toacetate (3.3 ml) were reacted according to the general pro-
cedure for compounds 1-3. White needle crystals [61,62]; 
mp: 170 °C (171-172.5 °C [60]), yield: 2.117 g (30%).  
 
IR: (KBr, vmax, cm-1): 3398, 2993, 1725, 1683, 1663, 1536. 
1
H-NMR: (400 MHz) (DMSO-d6/TMS, ppm): δ 1.17-1.19 (t, 
3H, CH3, J=6.8 Hz), 3.8 (dd, 2H, NHCH2), 4.1 (q, 2H, 
CH2CH3), 6.95 (m, 1H, benzene CH), 7.45 (m, 1H, benzene 
CH), 7.85 (t, 1H, CONHCH2), 7.9 (dd, 1H, benzene CH), 
8.35 (d, 1H, benzene CH), 10.2 (s, 1H, CNHCO), 13.2 (s, 
1H, COOH). 
5-Chloro-2-[3-(2-ethoxy-2-oxoethyl)ureido]benzoic acid 
(2). 2-Amino-5-chlorobenzoic acid (4.547 g, 0.026 mol) and 
ethyl isocyanoacetate (3.3 ml) were reacted according to the 
general procedure for compounds 1-3. Light yellow needle 
crystals; mp: 178.9 °C, yield: 2.950 g (37%). IR: (KBr, vmax, 
cm
-1
): 3336, 3041, 2980, 2928, 1732, 1690, 1650. 
1
H-NMR 
(400 MHz) (DMSO-d6/TMS, ppm): δ 1.18 (t, 3H, CH3, 
J=7.2 Hz), 3.81 (d, 2H, NHCH2CO, J=6.0 Hz), 4.10 (q, 2H, 
CH2CH3, J=7.2 Hz), 7.53 (q, 1H, benzene CH, J=8.8 Hz, 
J=2.8 Hz), 7.83 (d, 1H, benzene CH, J=2.4 Hz), 7.95 (s, 1H, 
CONHCH2), 8.37 (d, 1H, benzene CH, J=8.8 Hz), 10.16 (s, 
1H, CNHCO), 13.60 (s, 1H, COOH). Anal. calc. for 
C12H13ClN2O5 (300.6948); C, 47.93; H, 4.36; N, 9.32. 
Found: C, 47.53; H, 4.00; N, 9.39. 
2-[3-(2-Ethoxy-2-oxoethyl)ureido]-4,5-dimethoxybenzo-
ic acid (3). 2-Amino-4,5-dimethoxybenzoic acid (5.226 g, 
0.026 mol) and ethyl isocyanoacetate (3.3 ml) were reacted 
according to the general procedure for compounds 1-3. Light 
brown colored needle shaped crystals; mp: 172.5 °C, yield: 
4.688 g, (54%). IR (KBr, vmax, cm-1): 3397, 3020, 2912, 
1738, 1684, 1615, 1539. 
1
H-NMR (400 MHz) (DMSO-d6): 
1.20 (t, 3H, OCH2CH3, J=7.2 Hz), 3.73 (s, 3H, OCH3), 3.77 
(s, 3H, OCH3), 3.82 (d, 2H, NHCH2, J=6.0 Hz), 4.11 (q, 2H, 
OCH2CH3, J=7.2 Hz), 7.37 (s, 1H, benzene CH), 7.92 (s, 1H, 
NHCH2), 8.16 (s, 1H, benzene CH), 10.34 (s, 1H, CNHCO), 
13.07 (s, 1H, COOH). Anal. calc. for C14H18N2O7.1/2H2O: 
C, 50.15; H, 5.71; N, 8.35. Found: C, 49.73; H, 5.30; N, 
8.39. 
General procedure for compounds 4-6. Compounds 1-
3 (0.011 mol) and 30 ml of concentrated hydrochloric acid 
were refluxed for 2 hours. The mixture was cooled and di-
luted with water to give compounds 4-6. 
 













Compound A HUH-7 MCF-7 HCT-116 
25 4-chlorobenzyl - - 16.9 
26 3-(trifluoromethyl)phenyl - - 6.0 
29 cyclohexyl - - 11.4 
30 2-cyanophenyl - - 19.0 
31 diphenylmethyl - - 9.9 
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2-(2,4-Dioxo-1,2-dihydroquinazolin-3(4H)-yl)acetic 
acid (4). Compound 1 (3 g, 0.011 mol) was reacted accord-
ing to the general procedure for compounds 1-3. White pow-
dered compound; mp: 295 °C (290-292 °C [63], 297-299 °C 
[64]), yield: 1.742 g (73%). IR (KBr, vmax, cm-1): 3285, 3010, 
2945, 1716, 1657, 1625, 1494. 
1
H-NMR (400 MHz) 
(DMSO-d6): 4,56 (s, 2H, CH2), 7.21-7.27 (m, 2H, benzene 
CH), 7.87-7.73 (m, 1H, benzene CH), 7.95 (dd, 1H, benzene 
CH, J=8.0 Hz, J=1.2 Hz), 11.62 (s, 1H, NH), 13.35 (s, 1H, 
COOH). 
2-(6-Chloro-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-
yl)acetic acid (5). Compound 2 (3.4 g, 0.011 mol) was re-
acted according to the general procedure for compounds 1-3. 
Light yellow needle shaped crytalline compound; mp: 300 
°C (dec) (327-329 °C [64,65]), yield: 1.027 g (36%). IR 
(KBr, vmax, cm-1): 3071, 2930, 1716, 1656. 1H-NMR (400 
MHz) (DMSO-d6): 4.56 (s, 2H, CH2), 7.25 (d, 1H, benzene 
CH, J=8.8 Hz), 7.77 (dd, 1H, benzene CH, J=8.8 Hz, J=2.8 
Hz), 7.89 (d, 1H, benzene CH, J=2.8 Hz), 11.78 (s, 1H, NH), 
13.09 (s, 1H, COOH). Anal. calc. for C10H7ClN2O4: C, 
47.17; H, 2.77; N, 11.00. Found: C, 47.13; H, 3.06; N, 10.98. 
2-(6,7-Dimethoxy-2,4-dioxo-1,2-dihydroquinazolin-3(4-
H)-yl)acetic acid (6). Compound 3 (3.69 g, 0.0113 mol) was 
reacted according to the general procedure for compounds 1-
3. Light creamy colored powdered crystalline compound; 
mp: 300 °C (dec), yield: 1.251 g (40%). IR (KBr, vmax, cm-1): 
3017, 2959, 1702, 1620, 1513, 1468. 
1
H-NMR (400 MHz) 
(DMSO-d6): 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.54 
(s, 2H, CH2), 6.71 (s, 1H, benzene CH), 7.29 (s, 1H, benzene 
CH), 11.38 (s, 1H, NH), 12.96 (s, 1H, COOH). Anal. calc. 
for C12H12N2O6: C, 51.43; H, 4.32; N, 10.00. Found: C, 
51.24; H, 4.03; N, 9.94. 
General procedure for compounds 7-34. A mixture of 
compound 4-6 (1 mmol) in 5 ml of dry DCM and piperazine 
derivative (1 mmol) was cooled in an ice bath. Then, 1.1 
mmol of DCC in 5 ml of dry dichloromethane was added to 
the mixture under nitrogen (N2) atmosphere. Reaction mix-
ture was stirred for 0.5 hour in an ice bath, then 10-16 hours 
at room temperature. Reaction solvent was evaporated to the 
dryness. Residue was dissolved in hot acetonitrile then 
cooled in refrigerator to get the DCU precipitated. White 
crystalline DCU was removed by filtration. Liquid part was 
evaporated and crystallized from appropriate solvents to give 
compound 7-34 
3-{2-[4-(4-Chlorobenzyl)piperazin-1-yl]-2-oxoethyl}qui-
nazoline-2,4(1H,3H)-dione (7). Compound 4 (0.220 g, 1 
mmol) and 1-(4-chlorobenzyl)piperazine (0.211 g, 1 mmol) 
were reacted according to the general procedure for com-
pounds 7-34 and the crude product was crystallized from 
methanol-ether mixture to give compound 7 as white pow-
der; mp: 300 °C (dec), yield: 91 mg (11%). ). IR (KBr, vmax, 
cm
-1
): 3276, 3030, 2928, 2850, 1729, 1639, 1491. 
1
H-NMR 
(400 MHz) (DMSO-d6/TMS, δ, ppm): 2.34 (t, 2H, piperazine 
CH2, J=4.4 Hz), 2.43 (t, 2H, piperazine CH2, J=4.4 Hz), 
3.44 (t, 2H, piperazine CH2, J=4.4 Hz), 3.52 (s, 2H, benzyl 
CH2), 3.57 (t, 2H, piperazine CH2, J=4.4 Hz), 4.74 (s, 2H, 
CH2CO), 7.20-7.24 (m, 2H, benzene CH), 7.35-7.42 (dd, 4H,  
 
 
J=8.4 Hz, J=1.6 Hz, benzyl CH), 7.67-7.71 (m, 1H, benzene 
CH), 7.90-7.93 (m, 1H, benzene CH), 11.53 (bs, 1H, NH). 
Anal. calc. for C21H21ClN4O3: C, 61.09; H, 5.13; N, 13.57. 
Found: C, 60.98; H, 5.013; N, 13.52. 
3-{2-[4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl]-
2-oxoethyl}quinazoline-2,4(1H,3H)-dione (8). Compound 4 
(0.220 g, 1 mmol) and 1-piperonylpiperazine (0.220 g, 1 
mmol) were reacted according to the general procedure for 
compounds 7-34 and the crude product was crystallized from 
ethanol to give compound 8 as white powdered compound; 
mp: 218.2 °C, yield: 28 mg (7%). IR (KBr, vmax, cm-1): 3292, 
3071, 3009, 2928, 2850, 1731, 1643, 1494. 
1
H-NMR (400 
MHz) (DMSO-d6): 2.32 (t, 2H, CH2 piperazine, J=4.8 Hz), 
2.42 (t, 2H, CH2 piperazine, J=4.8 Hz), 3.44 (m, 4H, 
piperazine CH2 and OCH2O), 3.56 (t, 2H, piperazine CH2, 
J=4.8 Hz), 4.73 (s, 2H, CH2CO), 6.0 (s, 2H, NCH2C6H5), 
6.76-7.25 (m, 3H, CH benzodioxol), 7.20-7.25 (m, 2H, ben-
zene CH), 7.67-7.71 (m, 1H, benzene CH), 7.90-7.93 (m, 
1H, benzene CH), 11.53 (bs, 1H, NH). Anal. calc. for 
C22H22N4O5 . 1/2 H2O: C, 61.24; H, 5.37; N, 12.99. Found: 
C, 61.13; H, 5.064; N, 12.88. 
3-{2-[4-(2-Furoyl)piperazin-1-yl]-2-oxoethyl}quinazoli-
ne-2,4(1H,3H)-dione (9). Compound 4 (0.220 g, 1 mmol) 
and 1-(2-furoyl)piperazine (0.180 g, 1 mmol) were reacted 
according to the general procedure for compounds 7-34 and 
the crude product was crystallized from n-hexane-ethanol 
mixture to give light yellow powdered compound; mp: 228 
°C, yield: 320 mg (84%). IR vmax (cm-1): 3327, 3061, 2928, 
2851, 1718, 1655, 1625, 1492, 1244. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 3.54 (t, 4H, piperazine CH2), 3.70 
(t, 4H, piperazine CH2), 4.80 (s, 2H, CH2CO), 6.65 (t, 1H, 
furoyl CH, J=1.6 Hz), 7.05-7.06 (m, 1H, furoyl CH), 7.21-
7.25 (m, 2H, benzene CH), 7.68-7.71 (m, 1H, benzene CH), 
7.88-7.94 (m, 2H, benzene CH and furoyl CH), 11.55 (bs, 
1H, NH). Anal. calc. for C19H18N4O5 . 1/9 H2O: C, 59.37; H, 
4.78; N, 14.58. Found: C, 59.18; H, 4.20; N, 14.35. 
3-[2-(4-Cyclohexylpiperazin-1-yl)-2-oxoethyl]quinazoli-
ne-2,4(1H,3H)-dione (10). Compound 4 (0.220 g, 1 mmol) 
and 1-cyclohexylpiperazine (0.168 g, 1 mmol) were reacted 
according to the general procedure for compounds 7-34 and 
the crude product was crystallized from methanol-ether mix-
ture to give white powdered compound; mp: 260.1 °C,  
yield: 23 mg (6%). IR (KBr, vmax, cm-1): 3327, 3060, 2928, 
2852, 1719, 1657, 1623, 1493. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 1.06-1.21 (m, 5H, cyclohexyl 
CH2), 1.54-1.72 (m, 5H, cyclohexyl CH2), 2.26-2.31 (m, 1H, 
cyclohexyl CH), 2.42 (t, 2H, piperazine CH2, J=4.8 Hz), 
2.52 (t, 2H, piperazine CH2, J=4.8 Hz), 3.38 (t, 2H, 
piperazine CH2, J=4.8 Hz), 3.49 (t, 2H, piperazine CH2, 
J=4.8 Hz), 4.70 (s, 2H, CH2CO), 7.17-7.22 (m, 2H, benzene 
CH), 7.64-7.68 (m, 1H, benzene CH), 7.89 (dd, 1H, benzene 
CH, J=7.6 Hz, J=1.6 Hz), 11.49 (bs, 1H, NH). Anal. calc. for 
C20H26N4O3: C, 64.84; H, 7.07; N, 15.12. Found: C, 65.26; 
H, 7.28; N, 15.35. 
2-{4-[(2,4-Dioxo-1,4-dihydroquinazolin-3(2H)-yl)acet-
yl]piperazin-1-yl}benzonitrile (11). Compound 4 (0.220 g, 1 
mmol) and 1-(2-cyanophenyl)piperazine (0.187 g, 1 mmol)  
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were reacted according to the general procedure for com-
pounds 7-34 and the crude product was crystallized from 
methanol-ether mixture to give yellow powdered compound; 
mp: 256.4 °C, yield: 173 mg (45%). IR (KBr, vmax, cm-1): 
3273, 3072, 3003, 2962, 2872, 2214, 1727, 1670, 1640, 
1489, 1455. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 
3.13 (t, 2H, piperazine CH2), 3.25 (t, 2H, piperazine CH2), 
3.63 (t, 2H, piperazine CH2), 3.77 (t, 2H, piperazine CH2), 
4.81 (s, 2H, CH2CO), 7.13 (t, 1H, 2-cyanophenyl CH, J=7.6 
Hz), 7.19-7.23 (m, 3H, 2-cyanophenyl CH and benzene 
CHs), 7.59-7.73 (m, 3H, 2-cyanophenyl CH and benzene 
CH), 7.92 (dd, 1H, benzene CH, J=7.2 Hz, J=1.2 Hz), 11.47 
(bs, 1H, NH). 
13
C-NMR (400 MHz) (DMSO-d6/TMS, δ, 
ppm): 41.91, 42.12, 44.77, 51.31, 51.98, 105.59, 113.90, 
115.68, 118.57, 119.88, 122.95, 123.11, 127.85, 134.67, 
134.84, 135.67, 139.88, 150.48, 155.32, 162.19, 165.41. MS 
(ESI
+
, m/z): 390.2 ([M
+
], base peak), 162.7 (C8H6N2O2, 
%10), 229.2 (C13H15N3O, %12). Anal. calc. for C21H19N5O3: 
C, 64.77, H, 4.92; N, 17.98. Found: C, 65.54; H, 4.70; N, 
17.64. 
3-{2-[4-(Diphenylmethyl)piperazin-1-yl]-2-oxoethyl}qui-
nazoline-2,4(1H,3H)-dione (12). Compound 4 (0.220 g, 1 
mmol) and 1-(diphenylmethyl)piperazine (0.252 g, 1 mmol) 
were reacted according to the general procedure for com-
pounds 7-34 and the crude product was crystallized from 
acetone-ether mixture to give white powdered compound; 
mp: 300 °C (dec), yield: 80 mg (18%). IR (KBr, vmax, cm-1): 
3207, 3061, 3025, 2924, 2859, 2805, 1727, 1655, 1492. 
1
H-
NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 2.29 (t, 2H, 
piperazine CH2), 2.37 (t, 2H, piperazine CH2), 3.47 (t, 2H, 
piperazine CH2), 3.60 (t, 2H, piperazine CH2), 4.38 (s, 1H, 
CH), 4.71 (s, 2H, CH2CO), 7.19-7.24 (m, 2H, benzene CH), 
7.30-7.34 (m, 6H, diphenyl CH), 7.46 (d, 4H, diphenyl CH, 
J=7.6 Hz), 7.66-7.70 (m, 1H, benzene CH), 7.91 (q, 1H, 
benzene CH, J=8.0 Hz, J=1.2 Hz), 11.51 (bs, 1H, NH). 
Anal. calc. for C27H26N4O3 . 1/3 H2O: C, 70.42; H, 5.84; N, 
12.17. Found: C, 70.37; H, 5.81; N, 12.12. 
3-[2-(4-Benzoylpiperazin-1-yl)-2-oxoethyl]quinazoline-
2,4(1H,3H)-dione (13). Compound 4 (0.220 g, 1 mmol) and 
1-benzoylpiperazine (0.190 g, 1 mmol) were reacted accord-
ing to the general procedure for compounds 7-34 and the 
crude product was crystallized from methanol-ether mixture 
to give white powdered compound; mp: 257 °C, yield: 110 
mg (28%). IR (KBr, vmax, cm-1): 3274, 3065, 3001, 2959, 
2911, 2860, 1726, 1676, 1617, 1492. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS) δ ppm: 3.30-3.60 (m, 8H, piperazine CH2), 
4.79 (s, 2H, CH2CO), 7.20-7.25 (m, 2H, benzene CH), 7.45-
7.49 (m, 5H, benzoyl CH), 7.67-7.72 (m, 1H, benzene CH), 
7.93 (dd, 1H, benzene CH, J=4 Hz, J=1.2 Hz), 11.55 (bs, 
1H, NH). Anal. calc. for C21H20N4O4: C, 64.28; H, 5.14; N, 
14.28. Found: C, 4.12; H, 4.75; N; 14.08. 
3-[2-Oxo-2-(4-pyridin-4-ylpiperazin-1-yl)ethyl]quinazo-
line-2,4(1H,3H)-dione (14). Compound 4 (0.220 g, 1 mmol) 
and 1-(4-pyridyl)piperazine (0.163 g, 1 mmol) were reacted 
according to the general procedure for compounds 7-34 and 
the crude product was crystallized from methanol-ether mix-
ture to give white powdered compound, mp: 300 °C (dec), 
yield: 24 mg (7%). IR (KBr, vmax, cm-1): 3178, 3089, 3003,  
 
 
2944, 1708, 1659, 1514. 
1
H-NMR (400 MHz) (DMSO-
d6/TMS, δ, ppm): 3.35 (t, 2H, piperazine CH2), 3.45 (t, 2H, 
piperazine CH2), 3.58 (t, 2H, piperazine CH2), 3.75 (t, 2H, 
piperazine CH2), 4.80 (s, 2H, CH2CO), 6.85 (dd, 2H, pyri-
dine CH, J=4.0 Hz, J=1.2 Hz), 7.23 (m, 2H, benzene CH), 
7.70 (m, 1H, benzene CH), 7.95 (dd, 1H, benzene CH), 8.20 
(dd, 2H, pyridine CH), 11.55 (bs, 1H, NH). Anal. calc. for 
C19H19N5O3 . 2/3 H2O (365.3861 g/mol); C, 60.47; H, 5.43; 
N, 18.56. Found: C, 60.27; H, 5.49; N, 18.65. 
3-{2-[4-(4-Chlorobenzyl)piperazin-1-yl]-2-oxoethyl}-6-
chloro-quinazoline-2,4(1H,3H)-dione (15). Compound 5 
(0.255 g, 1 mmol) and 1-(4-chlorobenzyl)piperazine (0.211 
g, 1 mmol) were reacted according to the general procedure 
for compounds 7-34 and the crude product was crystallized 
from methanol-ether mixture to give white powdered com-
pound; mp: 300 °C (dec), yield: 39 mg (9%). IR (KBr, vmax, 
cm
-1
): 3503, 3060, 2916, 1726, 1662, 1457. 
1
H-NMR (400 
MHz) (DMSO-d6/TMS, δ, ppm): 2.32 (t, 2H, piperazine 
CH2, J=4.4 Hz), 2.41 (t, 2H, piperazine CH2, J=4.4 Hz), 
3.42 (t, 2H, piperazine CH2, J=4.8 Hz), 3.50 (s, 2H, benzyl 
CH2), 3.54 (t, 2H, piperazine CH2, J=4.4 Hz), 4.71 (s, 2H, 
CH2CO), 7.22 (d, 1H, benzene CH, J=9.2 Hz), 7.33-7.40 (m, 
4H, benzyl CH), 7.75 (dd, 1H, benzene CH, J=8.8 Hz, J=2.8 
Hz), 7.84 (d, 1H, benzene CH, J=2.4 Hz), 11.67 (bs, 1H, 
NH). Anal. calc. for C21H20Cl2N4O3. 1/2 H2O (447.3141 
g/mol): C, 55.27; H, 4.64; N, 12.28. Found: C, 55.00; H, 
4.55; N, 12.29. 
6-Chloro-3-(2-oxo-2-{4-[3-(trifluoromethyl)phenyl]pip-
erazin-1-yl}ethyl) quinazoline-2,4(1H,3H)-dione (16). Com-
pound 5 (0.255 g, 1 mmol) and 1-(3-trifluoromethylphenyl) 
piperazine (0,230 g, 1 mmol) were reacted according to the 
general procedure for compounds 7-34 and the crude product 
was crystallized from methanol-ether mixture to give white 
powdered compound; mp: 300 °C (dec), yield: 38 mg (9%). 
IR (KBr, vmax, cm-1): 3067, 2927, 1725, 1668, 1232, 1118, 
1075. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 2.23 
(t, 2H, piperazine CH2, J=4.8 Hz), 3.35 (t, 2H, piperazine 
CH2), 3.59 (t, 2H, piperazine CH2, J=4.8 Hz), 3.73 (t, 2H, 
piperazine CH2, J=4.8 Hz), 4.80 (s, 2H, CH2CO), 7.10 (d, 
1H, 3-(trifluoromethyl)phenyl CH, J=7.2 Hz), 7.21-7.26 (m, 
2H, 3-(trifluoromethyl)phenyl CH), 7.23 (d, 1H, benzene 
CH, J=8.8 Hz), 7.44 (t, 1H, 3-(trifluoromethyl)phenyl CH, 
J=8.0 Hz), 7.74 (dd, 1H, benzene CH, J=8.8 Hz, J=2.4 Hz), 
7.85 (d, 1H, benzene CH, J=2.4 Hz), 11.70 (bs, 1H, NH). 
Anal. calc. for C21H18ClF3N4O3 (466.8407 g/mol): C, 54.03; 
H, 3.89; N, 12.00. Found: C, 53.75; H, 3.77; N, 12.07. 
3-{2-[4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl]-
2-oxoethyl}-6-chloroquinazoline-2,4(1H,3H)-dione (17). 
Compound 5 (0.255 g, 1 mmol) and 1-piperonylpiperazine 
(0.220 g, 1 mmol) were reacted according to the general pro-
cedure for compounds 7-34 and the crude product was 
washed with acetone and hot methanol to give white pow-
dered compound; mp: 300 °C (dec), yield: 22 mg (5%). IR 
(KBr, vmax, cm-1): 3058, 2915, 1719, 1659, 1491. 1H-NMR 
(400 MHz) (DMSO-d6/TMS, δ, ppm): 2.31 (t, 2H, piperazine 
CH2), 2.40 (t, 2H, piperazine CH2), 3.42 (s, 4H, piperazine 
CH2 and OCH2O), 3.53 (t, 2H, piperazine CH2), 4.71 (s, 2H, 
CH2CO), 5.97 (s, 2H, NCH2C6H3), 6.74-6.87 (m, 3H,  
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benzodioxol CH), 7.22 (d, 1H, benzene CH, J=8.4 Hz), 7.72 
(dd, 1H, benzene CH, J=8.8 Hz, J=2.4 Hz), 7.84 (d, 1H, 
benzene CH, J=2.0 Hz), 11.70 (bs, 1H, NH). Anal. calc. for 
C22H21ClN4O5 . 2/3 H2O (456.8788 g/mol): C, 54.61; H, 
5.00; N, 11.58. Found: C, 54.46; H, 5.19; N, 11.25. 
6-Chloro-3-{2-[4-(2-furoyl)piperazin-1-yl]-2-oxoethyl}-
quinazoline-2,4(1H,3H)-dione (18). Compound 5 (0.255 g, 
1 mmol) and 1-(2-furoyl)piperazine (0.180 g, 1 mmol) were 
reacted according to the general procedure for compounds 7-
34 and the crude product was washed with hot methanol to 
give white powdered compound; mp: 294.5 °C, yield: 89 mg 
(21%). IR (KBr, vmax, cm-1): 3054, 2931, 1718, 1655, 1486. 
1
H-NMR (400 MHz) (DMSO-d6 / TMS) δ ppm: 3.28 (t, 2H, 
piperazine CH2), 3.52 (t, 2H, piperazine CH2), 3.67-3.75 (m, 
4H, piperazine CH2), 4.78 (s, 2H, CH2CO), 6.64 (dd, 1H, 
furoyl CH, J=3.6 Hz, J=2.0 Hz), 7.04 (d, 1H, furoyl CH, 
J=2.8 Hz), 7.23 (d, 1H, benzene CH, J=8.4 Hz), 7.74 (dd, 
1H, benzene CH, J=8.8 Hz, J=2.4 Hz), 7.85-7.86 (m, 2H, 
benzene CH and furoyl CH), 11.75 (bs, 1H, NH). Anal. calc. 
for C19H17ClN4O5 (416.8149 g/mol): C, 53.97; H, 4.21; N, 
13.25. Found: C, 54.18; H, 4.12; N, 13.35. 
6-Chloro-3-[2-(4-cyclohexylpiperazin-1-yl)-2-oxoethyl] 
quinazoline-2,4(1H,3H)-dione (19). Compound 5 (0.255 g, 
1 mmol) and 1-cyclohexylpiperazine (0.168 g, 1 mmol) were 
reacted according to the general procedure for compounds 7-
34 and the crude product was washed with hot methanol to 
give white powdered compound; mp: 300 °C (dec), yield: 36 
mg (9%). IR (KBr, vmax, cm-1): 3068, 2925, 1722, 1660. 1H-
NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 1.16-1.22 (m, 
5H, cyclohexyl), 1.54-1.73 (m, 5H, cyclohexyl), 2.26 (1H, 
m, cyclohexyl CH), 2.43 (t, 2H, piperazine CH2, J=4.4 Hz), 
2.53 (t, 2H, piperazine CH2, J=4.8 Hz), 3.39 (t, 2H, 
piperazine CH2, J=4.8 Hz), 3.50 (t, 2H, piperazine CH2, 
J=4.8 Hz), 4.71 (s, 2H, CH2CO), 7.22 (d, 1H, benzene CH, 
J=8.8 Hz), 7.72 (dd, 1H, benzene CH, J=8.8 Hz, J=2.4 Hz), 
7.83 (d, 1H, benzene CH, J=2.0 Hz), 11.68 (bs, 1H, NH). 
Anal. calc. for C20H25ClN4O3 .1/3 H2O (404.8904 g/mol): C, 
58.46; H, 6.30; N, 13.64. Found: C, 58.02; H, 6.00; N, 13.53. 
2-{4-[2-(6-Chloro-2,4-dioxo-1,2-dihydroquinazolin-
3(4H)-yl)acetyl]piperazin-1-yl}benzonitrile (20). Compound 
5 (0.255 g, 1 mmol) and 1-(2-cyanophenyl)piperazine (0.187 
g, 1 mmol) were reacted according to the general procedure 
for compounds 7-34 and the crude product was washed with 
hot methanol to give white powdered compound; mp: higher 
than 300 °C, yield: 172 mg (41%). IR (KBr, vmax, cm-1): 
3188, 3069, 2961, 2928, 2860, 2224, 1714, 1663, 1489. 
1
H-
NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 3.14 (t, 2H, 
piperazine CH2), 3.24 (t, 2H, piperazine CH2), 3.64 (t, 2H, 
piperazine CH2), 3.78 (t, 2H, piperazine CH2), 4.83 (s, 2H, 
CH2CO), 7.15 (t, 1H, 2-cyanophenyl CH, J=7.6 Hz), 7.21-
7.26 (m, 2H, benzene CH and 2-cyanophenyl CH), 7.62-7.66 
(m, 1H, benzene CH), 7.74-7.78 (m, 2H, 2-cyanophenyl 
CH), 7.87 (d, 1H, benzene CH, J=2.8 Hz), 11.72 (s, 1H, 
NH). 
13
C-NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 42.06, 
42.17, 44.81, 51.28, 51.94, 105.58, 115.33, 117.98, 119.88, 
118.54, 122.92, 126.74, 127.12, 134.66, 134.80, 135.58, 









], base peak). Anal. calc. for 
C21H18ClN5O3 . 1/5 H2O (423.8522 g/mol): C, 59.01; H, 
4.34; N, 16.38. Found: C, 58.97; H, 4.26; N, 16.30. 
6-Chloro-3-{2-[4-(diphenylmethyl)piperazin-1-yl]-2-
oxoethyl}quinazoline-2,4(1H,3H)-dione (21). Compound 5 
(0.255 g, 1 mmol) and 1-(diphenylmethyl)piperazine (0.252 
g, 1 mmol) were reacted according to the general procedure 
for compounds 7-34 and the crude product was washed with 
hot methanol to give white powdered compound; mp: 300 °C 
(dec), yield: 45 mg (18%). IR (KBr, vmax, cm-1): 3187, 3062, 
2851, 2928, 1727, 1655, 1491. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 2.29 (t, 2H, piperazine CH2), 2.37 
(t, 2H, piperazine CH2), 3.46 (t, 2H, piperazine CH2), 3.59 (t, 
2H, piperazine CH2), 4.38 (s, 1H, CH), 4.71 (s, 2H, CH2CO), 
7.19-7.24 (m, 1H, benzene CH), 7.30-7.34 (m, 6H, diphenyl 
CH), 7.45-7.47 (m, 4H, diphenyl CH), 7.74 (dd, 1H, benzene 
CH, J=8.8 Hz, J=2.4 Hz), 7.86 (d, 1H, benzene CH, J=2.8 
Hz), 11.69 (bs, 1H, NH). Anal. calc. for C27H25ClN4O3 . 2/3 
H2O (488.9653 g/mol): C, 64.73; H, 5.30; N, 11.18. Found: 
C, 64.86; H, 5.29; N, 10.85. 
6-Chloro-3-{2-[4-(4-methoxyphenyl)piperazin-1-yl]-2-
oxoethyl}quinazoline-2,4(1H,3H)-dione (22). Compound 5 
(0.255 g, 1 mmol) and 1-(4-methoxyphenyl)piperazine 
(0.192 g, 1 mmol) were reacted according to the general pro-
cedure for compounds 7-34 and the crude product was 
washed with acetone and hot methanol to give white pow-
dered compound; mp: 300 °C (dec), yield: 102 mg (24%). IR 
(KBr, vmax, cm-1): 3067, 2928, 1724, 1655, 1512. 1H-NMR 
(400 MHz) (DMSO-d6/TMS, δ, ppm): 2.97 (t, 2H, piperazine 
CH2), 3.01 (t, 2H, piperazine CH2), 3.57 (t, 2H, piperazine 
CH2), 3.68 (s, 3H, OCH3), 3.70 (t, 2H, piperazine CH2), 4.78 
(s, 2H, CH2CO), 6.82-6.94 (m, 4H, methoxyphenyl CH), 
7.23 (d, 1H, benzene CH, J=8.8 Hz), 7.73 (dd, 1H, benzene 
CH, J=8.8 Hz, J=2.4 Hz), 7.84 (d, 1H, benzene CH, J=2.8 
Hz), 11.63 (bs, 1H, NH). Anal. calc. for C21H21ClN4O4 . 2/3 
H2O (428.8687g/mol): C, 57.21; H, 5.11; N, 12.71. Found: 
C, 56.95; H, 4.84; N, 12.68. 
3-[2-(4-Benzoylpiperazin-1-yl)-2-oxoethyl]-6-chloroqu-
inazoline-2,4(1H,3H)-dione (23). Compound 5 (0.255 g, 1 
mmol) and 1-benzoylpiperazine (0.190 g, 1 mmol) were re-
acted according to the general procedure for compounds 7-
34 and the crude product was washed with acetone and hot 
methanol to give white powdered compound; mp: 300 °C 
(dec), yield: 35 mg (8%). IR (KBr, vmax, cm-1): 3057, 2930, 
1715, 1660, 1618. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, 
ppm): 3.50 (t, 4H, piperazine CH2), 3.63 (t, 4H, piperazine 
CH2), 4.76 (s, 2H, CH2CO), 7.23 (d, 1H, benzene CH, J=8.8 
Hz), 7.42-7.46 (m, 5H, benzoyl CH), 7.73 (dd, 1H, benzene 
CH, J=8.8 Hz, J=2.4 Hz), 7.84 (d, 1H, benzene CH, J=2.4 
Hz), 11.64 (bs, 1H, NH). Anal. calc. for C21H19ClN4O4 . 2/3 
H2O (426.8528 g/mol): C, 57.47; H, 4.67; N, 12.77. Found: 
C, 57,05; H, 4,62; N, 12,69. 
6-Chloro-3-[2-oxo-2-(4-pyridin-4-ylpiperazin-1-yl)eth-
yl]quinazoline-2,4(1H,3H)-dione (24). Compound 5 (0.255 
g, 1 mmol) and 1-(4-pyridyl)piperazine (0.163 g, 1 mmol) 
were reacted according to the general procedure for com-
pounds 7-34 and the crude product was crystallized from 
methanol-ether mixture to give white powdered compound; 
mp: 300 °C (dec), yield: 24 mg (6%). IR (KBr, vmax, cm-1): 
3068, 2932, 1715, 1657, 1595. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 3.34 (t, 2H, piperazine CH2), 3.44 
(t, 2H, piperazine CH2, J=4.8 Hz), 3.56 (t, 2H, piperazine 
CH2, J=4.8 Hz), 3.71 (t, 2H, piperazine CH2, J=4.8 Hz), 4.80 
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(s, 2H, CH2CO), 6.83 (dd, 2H, pyridine CH, J=5.2 Hz, J=1.2 
Hz), 7.23 (d, 1H, benzene CH, J=8.4 Hz), 7.75 (dd, 1H, ben-
zene CH, J=8.8 Hz, J=2.4 Hz), 7.85 (d, 1H, benzene CH, 
J=2.8 Hz), 8.18 (d, 2H, pyridine CH, J=6.8 Hz), 11.70 (bs, 
1H, NH). Anal. calc. for C19H18ClN5O3 (399.8308 g/mol): C, 
57.07; H, 4.54; N, 17.52. Found: C, 57.49; H, 4.45; N, 17.13. 
3-{2-[4-(4-Chlorobenzyl)piperazin-1-yl]-2-oxoethyl}-
6,7-dimethoxyquinazoline-2,4(1H,3H)-dione (25). Com-
pound 6 (0.280 g, 1 mmol) and 1-(4-chlorobenzyl)piperazine 
(0.211 g, 1 mmol) were reacted according to the general pro-
cedure for compounds 7-34 and the crude product was crys-
tallized from methanol-ether mixture to give white powdered 
crystalline compound; mp: 300 °C (dec), yield: 25 mg (5%). 
IR (KBr, vmax, cm
-1
): 3096, 2955, 1718, 1657, 1513. 
1
H-
NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 2.30 (t, 2H, 
piperazine CH2), 2.40 (t, 2H, piperazine CH2), 3.41 (t, 2H, 
piperazine CH2), 3.49 (s, 2H, benzyl CH2), 3.54 (t, 2H, 
piperazine CH2), 3.76 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 
4.68 (s, 2H, CH2CO), 6.68 (s, 1H, benzene CH), 7.24 (s, 1H, 
benzene CH), 7.35 (dd, 4H, benzyl CH, J=17.6 Hz, J=8.8 
Hz), 11.27 (s, 1H, NH). Anal. calc. for C23H25ClN4O5 . 2/3 
H2O (472.9213 g/mol): C, 56.97; H, 5.47; N, 11.55. Found: 
C, 56.88; H, 5.85; N, 11.38. 
6,7-Dimethoxy-3-(2-oxo-2-{4-[3-(trifluoromethyl)phen-
yl]piperazin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione (26). 
Compound 6 (0.280 g, 1 mmol) and 1-(3-trifluoromethyl-
phenyl)piperazine (0,230 g, 1 mmol) were reacted according 
to the general procedure for compounds 7-34 and the crude 
product was crystallized from methanol-ether mixture to 
give white powdered crystalline compound; mp: 228 °C, 
yield: 41 mg (8%). IR (KBr, vmax, cm-1): 3079, 2958, 1705, 
1671, 1646, 1512. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, 
ppm): 3.24 (t, 2H, piperazine CH2, J=4.8 Hz), 3.32 (t, 2H, 
piperazine CH2), 3.60 (t, 2H, piperazine CH2), 3.75 (t, 2H, 
piperazine CH2), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
4.80 (s, 2H, CH2CO), 6.71 (s, 1H, benzene CH), 7.12 (d, 1H, 
3-(trifluoromethyl)phenyl CH, J=8.0 Hz), 7.23 (s, 1H, ben-
zene CH), 7.26-7.29 (m, 2H, 3-(trifluoromethyl)phenyl CH), 
7.46 (t, 1H, 3-(trifluoromethyl)phenyl CH, J=8.0 Hz), 11.34 
(s, 1H, NH). Anal. calc. for C23H23F3N4O5 (492.4479 g/mol): 




(27). Compound 6 (0.280 g, 1 mmol) and 1-piperonyl-
piperazine (0.220 g, 1 mmol) were reacted according to the 
general procedure for compounds 7-34 and the crude product 
was crystallized from methanol-ether mixture to give white 
powdered crystalline compound; mp: 211.3 °C, yield: 64 mg 
(15%). IR (KBr, vmax, cm-1): 3092, 2946, 1709, 1662, 1469. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 2.31 (t, 2H, 
piperazine CH2, J=4.8 Hz), 2.41 (t, 2H, piperazine CH2), 
3.31 (t, 2H, piperazine CH2), 3.43 (s, 2H, OCH2O), 3.55 (t, 
2H, piperazine CH2), 3.79 (s, 3H, OCH3), 3.84 (s, 3H, 
OCH3), 4.70 (s, 2H, CH2CO), 6.00 (s, 2H, NCH2-benzene), 
6.70 (s, 1H, benzene CH), 6.76-6.89 (m, 3H, benzodioxol 
CH), 7.27 (s, 1H, benzene CH), 11.30 (s, 1H, NH). Anal. 
calc. for C22H22N4O5 (422.434 g/mol): C, 59.74; H, 5.43; N, 
11.61. Found: C, 59.87; H, 5.20; N, 11.59. 
3-{2-[4-(2-Furoyl)piperazin-1-yl]-2-oxoethyl}-6,7-dime-
thoxyquinazoline-2,4(1H,3H)-dione (28). Compound 6 
(0.280 g, 1 mmol) and 1-(2-furoyl)piperazine (0.180 g, 1 
mmol) were reacted according to the general procedure for 
compounds 7-34 and the crude product was crystallized from 
ethanol to give white powdered crystalline compound; mp: 
300 °C (dec), yield: 79 mg (18%). IR (KBr, vmax, cm-1): 
3017, 2934, 1714, 1658, 1624, 1514. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS) δ ppm: 3.54 (t, 4H, piperazine CH2), 3.70 
(t, 4H, piperazine CH2), 3.80 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3), 4.78 (s, 2H, CH2CO), 6.65-6.66 (m, 1H, furoyl CH), 
6.71 (s, 1H, benzene CH), 7.06 (d, 1H, furoyl CH, J=3.6 
Hz), 7.28 (s, 1H, benzene CH), 7.88 (d, 1H, furoyl CH, 
J=0.8 Hz), 11.34 (s, 1H, NH). Anal. calc. for 
C21H22N4O7.3H2O (442.4221 g/mol): C, 50.80; H, 5.68; N, 
11.29. Found: C, 51.08; H, 5.77; N, 11.34.  
3-[2-(4-Cyclohexylpiperazin-1-yl)-2-oxoethyl]-6,7-dime-
thoxyquinazoline-2,4(1H,3H)-dione (29). Compound 6 
(0.280 g, 1 mmol) and 1-cyclohexylpiperazine (0.168 g, 1 
mmol) were reacted according to the general procedure for 
compounds 7-34 and the crude product was crystallized from 
methanol-ether mixture to give white powdered crystalline 
compound; mp: 239.7 °C, yield: 74 mg (17%). IR (KBr, vmax, 
cm
-1
): 3084, 3008, 2926, 2856, 1702, 1661, 1512. 
1
H-NMR 
(400 MHz) (DMSO-d6/TMS, δ, ppm): 1.09-1.74 (m, 10H, 
cyclohexyl CH2), 2.30 (m, 1H, cyclohexyl CH), 2.45 (t, 2H, 
piperazine CH2, J=4.0 Hz), 2.54 (t, 2H, piperazine CH2), 
3.41 (t, 2H, piperazine CH2, J=3.6 Hz), 3.52 (t, 2H, 
piperazine CH2), 3.79 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 
4.70 (s, 2H, CH2CO), 6.70 (s, 1H, benzene CH), 7.26 (s, 1H, 
benzene CH), 11.30 (s, 1H, NH). Anal. calc. for C22H30N4O5 
. 1/4 H2O (430.4976 g/mol): C, 60.74; H, 7.07; N, 12.88. 
Found: C, 60.57; H, 7.19; N, 12.79. 
2-{4-[(6,7-Dimethoxy-2,4-dioxo-1,4-dihydroquinazolin-
3(2H)-yl)acetyl]piperazin-1-yl}benzonitrile (30). Compound 
6 (0.280 g, 1 mmol) and 1-(2-cyanophenyl)piperazine (0.187 
g, 1 mmol) were reacted according to the general procedure 
for compounds 7-34 and the crude product was crystallized 
from methanol-ether mixture to give white powdered crystal-
line compound; mp: 300 °C (dec), yield: 21 mg (5%). IR 
(KBr, vmax, cm-1): 3094, 2955, 2214, 1720, 1663, 1514. 1H-
NMR (400 MHz) (DMSO-d6/TMS, δ ppm): 3.13 (t, 2H, 
piperazine CH2), 3.24 (t, 2H, piperazine CH2), 3.64 (t, 2H, 
piperazine CH2), 3.78 ( t, 2H, piperazine CH2), 3.80 (s, 3H, 
OCH3), 3.85 (s, 3H, OCH3), 4.80 (s, 2H, CH2CO), 6.72 (s, 
1H, benzene CH), 7.15 (t, 1H, 2-cyanophenyl CH, J=7.6 
Hz), 7.22 (d, 1H, 2-cyanophenyl CH, J=8.0 Hz), 7.28 (s, 1H, 
benzene CH), 7.62-7.66 (m, 1H, 2-cyanophenyl CH), 7.76 
(dd, 1H, 2-cyanophenyl CH, J=8.0 Hz, J=1.6 Hz), 11.33 (s, 
1H, NH). Anal. calc. for C23H23N5O5 . H2O (449.4594 
g/mol): C, 59.09; H, 5.39; N, 14.98. Found: C, 58.85; H, 
5.24; N, 14.84. 
 3-{2-[4-(Diphenylmethyl)piperazin-1-yl]-2-oxoethyl}-
6,7-dimethoxyquinazoline-2,4(1H,3H)-dione (31). Com-
pound 6 (0.280 g, 1 mmol) and 1-(diphenylmethyl) 
piperazine (0.252 g, 1 mmol) were reacted according to the 
general procedure for compounds 7-34 and the crude product 
was crystallized from methanol-ether mixture to give white 
powdered crystalline compound; mp: 262.4°C, yield: 21 mg  
 
74    Letters in Drug Design & Discovery, 2016, Vol. 13, No. 1 Akgun et al. 
(4%). IR (KBr, vmax, cm-1): 3057, 2961, 2889, 1709, 1666, 
1511. 
1
H-NMR (400 MHz) (DMSO-d6/TMS, δ, ppm): 2.29 
(t, 2H, piperazine CH2), 2.36 (t, 2H, piperazine CH2), 3.46 (t, 
2H, piperazine CH2), 3.60 (t, 2H, piperazine CH2), 3.79 (s, 
3H, OCH3), 3.84 (s, 3H, OCH3), 4.38 (s, 1H, diphenyl CH), 
4.68 (s, 2H, CH2CO), 6.70 (s, 1H, benzene CH), 7.20 (t, 2H, 
diphenylmethyl CH, J=7.2 Hz), 7.26 (s, 1H, benzene CH), 
7.32 (t, 4H, diphenylmethyl CH, J=7.6 Hz), 7.46 (d, 4H, 
diphenylmethyl CH, J=7.2 Hz), 11.29 (s, 1H, NH). Anal. 
calc. for C29H30N4O5 (514.5725 g/mol): C, 67.69; H, 5.88; N, 
10.89. Found: C, 67.33; H, 6.01; N, 11.01. 
6,7-Dimethoxy-3-{2-[4-(4-methoxyphenyl)piperazin-1-
yl]-2-oxoethyl}quinazoline-2,4(1H,3H)-dione (32). Com-
pound 6 (0.280 g, 1 mmol) and 1-(4-methoxyphenyl) 
piperazine (0.192 g, 1 mmol) were reacted according to the 
general procedure for compounds 7-34 and the crude product 
was washed with hot acetonitrile and methanol to give white 
powdered crystalline compound; mp: 283.5 °C, yield: 120 
mg (26%). IR (KBr, vmax, cm-1): 3194, 3065, 3013, 2948, 
2886, 2830, 1723, 1659, 1513. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 2.99 (t, 2H, piperazine CH2, J=3.6 
Hz), 3.09 (t, 2H, piperazine CH2, J=3.6 Hz), 3.59 (t, 2H, 
piperazine CH2, J=3.6 Hz), 3.70 (s, 3H, 4-methoxyphenyl 
OCH3), 3.73 (t, 2H, piperazine CH2, J=3.6 Hz), 3.80 (s, 3H, 
OCH3), 3.86 (s, 3H, OCH3), 4.79 (s, 2H, CH2CO), 6.72 (s, 
1H, benzene CH), 6.91 (dd, 4H, 4-methoxyphenyl CH), 7.28 
(s, 1H, benzene CH), 11.33 (s, 1H, NH). 
13
C-NMR (400 
MHz) (DMSO-d6/TMS, δ, ppm): 41.72, 42.05, 44.62, 50.27, 
50.71, 55.62, 56.19, 56.31, 97.99, 105.98, 107.92, 114.75, 
118.58, 135.63, 145.58, 145.68, 150.58, 153.85, 155.56, 
161.69, 165.34. MS (ESI
+
, m/z): 455.2 ([M
+
], base peak), 
207.2 (C10H9NO4), 249.2 (C13H19N3O2), 262.9 (C12H11N2O5). 
Anal. calc. for C23H26N4O6 . 1/4 H2O (454.4759 g/mol): C, 
60.19; H, 5.82; N, 12.21. Found: C, 60.17; H, 5.84; N, 12.20. 
3-[2-(4-Benzoylpiperazin-1-yl)-2-oxoethyl]-6,7-dimetho-
xyquinazoline-2,4(1H,3H)-dione (33). Compound 6 (0.280 
g, 1 mmol) and 1-benzoylpiperazine (0.190 g, 1 mmol) were 
reacted according to the general procedure for compounds 7-
34 and the crude product was crystallized from methanol-
ether mixture to give white powdered crystalline compound; 
mp: 168.5 °C, yield: 32 mg (7%). IR (KBr, vmax, cm-1): 3010, 
2958, 1712, 1660, 1623, 1513. 
1
H-NMR (400 MHz) 
(DMSO-d6/TMS, δ, ppm): 3.51 (t, 4H, piperazine CH2), 3.66 
(t, 4H, piperazine CH2), 3.79 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3), 4.76 (s, 2H, CH2CO), 6.71 (s, 1H, benzene CH), 
7.27 (s, 1H, benzene CH), 7.45-7.49 (m, 5H, benzoyl CH), 
11.32 (s, 1H, NH). Anal. calc. for C23H24N4O6. 3 H2O 
(452.46 g/mol): C, 54.54; H, 5.97; N, 11.06. Found: C, 
54.68; H, 5.99; N, 11.15. 
6,7-Dimethoxy-3-[2-oxo-2-(4-pyridin-4-ylpiperazin-1-
yl)ethyl]quinazoline-2,4(1H,3H)-dione (34). Compound 6 
(0.280 g, 1 mmol) and 1-(4-pyridyl)piperazine (0.163 g, 1 
mmol) were reacted according to the general procedure for 
compounds 7-34 and the crude product was crystallized from 
methanol-ether mixture to give white powdered crystalline 
compound; mp: 300 °C (dec), yield: 32 mg (8%). IR (KBr, 
vmax, cm-1): 3068, 2932, 1715, 1657, 1510. 1H-NMR (400 
MHz) (DMSO-d6/TMS, δ, ppm): 3.33 (t, 2H, piperazine 
CH2), 3.43 (t, 2H, piperazine CH2, J=4.4 Hz), 3.54 (t, 2H, 
piperazine CH2, J=4.8 Hz), 3.70 (t, 2H, piperazine CH2, 
J=4.8 Hz), 3.77 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 4.76 (s, 
2H, CH2CO), 6.68 (s, 1H, benzene CH), 6.82 (dd, 2H, pyri-
dine CH, J=5.2 Hz, J=1.6 Hz), 7.25 (s, 1H, benzene CH), 
8.16 (dd, 2H, pyridine CH, J=5.2 Hz, J=1.6 Hz), 11.30 (s, 
1H, NH). Anal. calc. for C21H23N5O5 . 2 H2O (425.438 
g/mol): C, 54.66; H, 5.90; N, 15.18. Found: C, 54.72; H, 
5.79; N, 15.16. 
3.2. Biological Methods 
3.2.1. Anticancer Activity Test Procedure: Sulforhodamine 
B Assay 
Cells were plated in 96-well plates (1000-5000 cell/well 
in 200 μl) and grown for 24 hours at 37 °C before being 
treated with various concentrations of the tested compounds 
(from 2.5 to 40 μM). After 72 hours of incubation the me-
dium was aspirated, washed once with PBS (CaCl2-, MgCl2- 
free) (Gibco, Invitrogen), and then 50 μl of a cold (4 °C) 
solution of 10% (v/v) trichloroacetic acid (Merck) was 
added. Microplates were left for 1 hour at 4 °C. After aspira-
tion of the solution, plates were washed five times with 
deionized water and left to dry. 50 μl of a 0.4% (w/v) of sul-
forhodamine B solution was removed and the plates were 
washed five times with 1% acetic acid before air-drying. 
Bound sulforhodamine B solubilize in a 200 μl 10 mM Tris-
base solution and the plates were left on a plate shaker for 10 
minutes. The absorbance was read in a 96-well plate reader 
at 515 nm. 
CONCLUSION 
In conclusion, synthesized compounds generally showed 
moderate or no in vitro cytotoxic activity against HUH-7, 
MCF-7 and HCT-116 cell lines. 4-Chlorobenzyl, 3-
trifluoromethylphenyl and diphenyl derivatives generally 
exhibited better IC50 values when compered to others. For 
our further studies, 4-chlorobenzyl derivative (compound 7) 
was selected as a promising lead in order to generate more 
effective anticancer agents. In addition, when the hydrogens 
at sixth and seventh position of the 2,4-(1H,3H)-
quinazolinedione ring replaced by methoxy groups, cyto-
toxic activity did not increased but some selectivity was pro-
vided againts HCT-116 cell lines. This result will lead us to 
synthesize more selective derivatives in our future studies. 
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